YARTEMLEASSIST PATIENT SUPPORT PROGRAM
Live / Applied — Statement of use — registration review complete (as of 13 Mar 2026)
What this means for you
Not registered yet, but its 16 Jun 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97462726
- Mark type
- Design + words
- Filed
- 16 Jun 2022
- Published for opposition
- 20 Dec 2022
- Attorney of record
- Kelley B. Harrington
Goods and services
- Class 016 — Paper goods and printed matter: Printed publications in the nature of brochures, pamphlets, newsletters, written articles and guidebooks in the field of medical information and patient support
- Class 035 — Advertising and business services: Promoting awareness of patient support offerings for endothelial diseases and disorders, renal diseases, transplant complications, ischemia-reperfusion injury and hematological, autoimmune, neurological, immunological and inflammation-related disease and disorders; business administration of reimbursement and medical benefit information for endothelial diseases and disorders, renal diseases, transplant complications, hematological, neurological, immunological and inflammation-related disease and disorders and their treatment; and business administrative services for medical referrals
- Class 036 — Insurance and financial services: Providing a website featuring financial information regarding medical benefits and reimbursements available for medical expenses related thereto; insurance services, namely, benefits verification in the nature of insurance claims administration; and providing online information and financial assistance with insurance benefits and coverage for health care providers and patients in the field of endothelial diseases and disorders, renal diseases, transplant complications, hematological, neurological, immunological and inflammation-related disease and disorders
- Class 041 — Education and entertainment services: Educational services, namely, conducting educational programs in the fields of endothelial diseases and disorders, renal diseases, transplant complications, hematological, neurological, immunological and inflammation-related disease and disorders and treatment and patient support options for these conditions
Owner
- Omeros Corporation, Seattle, WA, US
- Omeros Corporation, Seattle, WA, US
Prosecution history
- 13 Mar 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 13 Mar 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 13 Mar 2026 — EXAMINER'S AMENDMENT ENTERED
- 13 Mar 2026 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 13 Mar 2026 — EXAMINERS AMENDMENT E-MAILED
- 13 Mar 2026 — SU-EXAMINER'S AMENDMENT WRITTEN
- 02 Mar 2026 — DATA MODIFICATION COMPLETED
- 24 Feb 2026 — ASSIGNED TO LIE
- 19 Feb 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 11 Feb 2026 — USE AMENDMENT FILED
- 11 Feb 2026 — TEAS STATEMENT OF USE RECEIVED
- 18 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 18 Dec 2025 — SOU EXTENSION 5 GRANTED
- 29 Jul 2025 — SOU EXTENSION 5 FILED
- 18 Dec 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL